Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» PureTech Receives Up To $36 Million from Roche to Develop Oral Delivery of Antisense Oligonucleotides
PureTech Receives Up To $36 Million from Roche to Develop Oral Delivery of Antisense Oligonucleotides
PureTech Receives Up To $36 Million from Roche to Develop Oral Delivery of Antisense Oligonucleotides
Submitted by
admin
on July 20, 2018 - 11:29am
Source:
CP Wire
News Tags:
PureTech
Roche
drug development
antisense
Headline:
PureTech Receives Up To $36 Million from Roche to Develop Oral Delivery of Antisense Oligonucleotides
snippet:
PureTech will be eligible to receive payments over $1 billion
The company has 11 products under development with affiliates
PureTech is focused on developing therapies based on the Brain-Immune-Gut Axis
Do Not Allow Advertisers to Use My Personal information
